Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.

Who May Be Eligible (Plain English)

Who May Qualify: - POAG/OHTN patients above the age of 18 years. - On a maximum of 2 IOP lowering medications. - Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year. Who Should NOT Join This Trial: - Glaucoma not of the POAG or OHTN variety or other retinal diseases. - Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes). - Using more than 2 IOP-lowering medications. - IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * POAG/OHTN patients above the age of 18 years. * On a maximum of 2 IOP lowering medications. * Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year. Exclusion Criteria: * Glaucoma not of the POAG or OHTN variety or other retinal diseases. * Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes). * Using more than 2 IOP-lowering medications. * IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.

Treatments Being Tested

DEVICE

Nanodropper

Nanodropper delivers 1/5 of eye drop volume compared to regular droppers

DEVICE

Regular dropper

Delivers full eye drop volume

Locations (1)

Wilford Hall Ambulatory Surgical Center
Lackland Air Force Base, Texas, United States